The newly designed quinazoline 4 (AURKA IC50 = 4.9; FLT3 IC50 = 127 nM) showed dual enzyme inhibition as well improved anti-proliferative activity in AML cell lines (EC50 ∼ 40 nM). This evidence concerns the gene AURKA and acute myeloid leukemia.